Short answer
Amphastar Pharmaceuticals, Inc. (AMPH) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $192M (up 0.3% year over year) with net income of $17M.
Q3 2025 key financials · XBRL
- Revenue
- $192M
- +0.3% YoY · +10.0% QoQ
- Net income
- $17M
- −57.1% YoY · −44.1% QoQ
- Operating margin
- 13.2%
- Gross margin
- 51.4%
- EPS (diluted)
- $0.37
- −52.6% YoY · −42.2% QoQ
Source: XBRL data from the Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2025 10-Q on SEC EDGAR. USD.
Amphastar Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New trade-policy risk: 10%–35% fentanyl-related tariffs and 10%–125% reciprocal tariffs imposed since February–April 2025
- Most materially updated risk: Pharmaceutical imports under U.S. Department of Commerce Section 232 investigation, creating potential additional tariffs
- Regulatory risk: Chinese trade restrictions could limit access to APIs and starting materials manufactured in China
- Operational risk: China facility supplies Amphadase and enoxaparin starting materials plus three APIs
- Financial risk: Lenders may force sales of pledged shares securing credit lines up to $57.0 million altogether
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amphastar Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.